ArticleJournal of cancer research and clinical oncology1986
Tumour karyotype may be important in the prognosis of human neuroblastoma.
Article in Journal of cancer research and clinical oncology, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma.Frontiers in oncology · 2025Review
- Comparison of Next-Generation Sequencing and Fluorescence In Situ Hybridization for Detection of Segmental Chromosomal Aberrations in Neuroblastoma.Diagnostics (Basel, Switzerland) · 2021Article
- Neuroblastoma tumour genetics: clinical and biological aspects.Journal of clinical pathology · 2001Review
- Do the ends justify the means?Nature medicine · 1995Article
- Biology of tumors of the peripheral nervous system.Cancer metastasis reviews · 1991Review
- Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression.British journal of cancer · 1988Article
- Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma.British journal of cancer · 1988Article
- Association of near-diploid DNA content and N-myc amplification in neuroblastomas.Clinical & experimental metastasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When comparing clinical and tumour cytogenetic data on 14 neuroblastoma patients in different stages of disease we found a high incidence of 1p abnormalities (12/12), homogeneously staining regions/double minutes (9/12) and 2p abnormalities (4/12) in 12 unresectable and metastatic tumours (clinical stages III and IV). In contrast, these features were absent in clinical stage II tumours (2/2) with good prognosis. The coincidence of 1p aberrations with poor outcome of disease will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.